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a b s t r a c t
No study has yet evaluated the relationship between arterial stiffness indexes and immuno-inflammatory
pathway in patients with an acute cardiovascular or cerebrovascular event. The aim of our study was to
evaluate in patients with acute ischemic stroke the relationship between immune-inflammatory markers
and arterial stiffness indexes.
Methods: 107 subjects with acute ischemic stroke and 107 controls without stroke. We evaluated
plasma levels of C-reactive protein (CRP), interleukin-1beta (IL-1), tumor necrosis factor-alpha (TNF-),
interleukin-6 (IL-6) and interleukin-10 (IL-10), E-selectin, P-selectin, intercellular adhesion molecule-1
(ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), von Willebrand Factor (vWF), tissue plasminogen
activator (TPA), plasminogen activator inhibitor-1 (PAI-1). Carotid-femoral pulse wave velocity (PWV)
and augmentation index (Aix) were evaluated.
Results: There was a significant positive relationship, corrected for age, and gender, between PWV and
CRP, TNF-, IL1, VWF and IL-6. Aix was significantly related to VWF, IL-6 and TNF- levels. Among
Lacunar subtype PWV was significantly related to CRP, IL-1, IL-6, TNF- and vWF. In LAAS subjects PWV
was significantly related to CRP, IL-1, IL-6, TNF- but not with vWF. Among CEI subtype, PWV was
significantly and positively related to CRP, IL-1, TNF- and vWF.
Discussion: Our findings show that both aortic stiffness and wave reflection are related to the degree
of systemic inflammation in stroke subjects, suggesting that circulating inflammation mediators can
influence the stiffness of vessels distant to those involved in the disease process itself.
© 2010 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Inflammation markers such as C-reactive protein (CRP) are pre-
dictive of stroke occurrence [1] and CRP has been reported elevated
in stroke patients [2], whereas our group [3,4] and other authors
[5,6] reported that some pro-inflammatory cytokines are system-
atically increased after ischemic stroke.
Although there are some inconsistencies, a number of recent
studies have suggested that in a healthy population, there may be a
significant relationship between CRP and measures of arterial stiff-
ness. Yasmin et al. found CRP to be related to pulse wave velocity
(PWV) but not to augmentation index (Aix) [9]. In contrast, Kampus
et al. found CRP to be independently and significantly associated
with Aix. Moreover in patients with systemic vasculitis, in which
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CRP levels are markedly elevated, they were positively correlated
with PWV and Aix [11].
Arterial stiffness is increasingly recognized as an important
determinant of cardiovascular risk [13–16] and may be directly
involved in the process of atherosclerosis [17]. The factors under-
lying increased arterial stiffness are incompletely understood,
but both functional and structural alterations in the vessel wall
are thought to be important. Indeed, some investigators have
shown that endothelial-derived nitric oxide (NO) regulates large
artery stiffness in vivo [12,18–21]. This may explain why other
cardiovascular risk factors such as diabetes mellitus and hyperc-
holesterolemia, which are associated with endothelial dysfunction,
are linked to premature arterial stiffening.
Few studies examined the relationship between arterial
stiffness indexes and systemic inflammation markers such as pro-
inflammatory cytokines [22], whereas no study has evaluated the
relationship between these indexes and immune-inflammatory
markers in patients with an acute cardiovascular or cerebrovascu-
lar event. Only one study [23] indirectly evaluated this relationship
and only with regard to erythrocyte sedimentation rate (ESR).
0021-9150/$ – see front matter © 2010 Elsevier Ireland Ltd. All rights reserved.
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On this basis the aim of our study was to evaluate the rela-
tionship between arterial stiffness and cytokine, selectin, adhesion




We enrolled all consecutive patients with a diagnosis of acute
ischemic stroke admitted to the Internal Medicine Department at
the University of Palermo between November 2006 and January
2008, and hospitalized control patients without a diagnosis of acute
ischemic stroke. Control subjects were patients admitted, in the
same period, to our Internal Medicine Department, for any cause
other than acute cardiovascular and cerebrovascular events.
Stroke was defined by focal neurological signs or symptoms
thought to be of vascular origin that persisted for >24 h confirmed
by brain CT and/or MRI in baseline conditions and brain CT with
contrast medium after 48–72 h [9].
In order to match patients with acute ischemic stroke and con-
trols for cardiovascular risk and previous cardiovascular morbidity,
controls were included if they had vascular risk factors or a history
of myocardial infarction or cerebrovascular disease or peripheral
vascular disease, but they were excluded if they had either current
or recent (within 6 months) cerebrovascular disease or one of the
exclusion criteria (see above).
Cardiovascular risk factors were evaluated for both cases and
controls on the basis of the criteria shown below. Hypercholes-
terolemia was defined as the presence of total cholesterol blood
levels ≥200 mg/dl. Hypertension was defined as present if sub-
jects had been previously diagnosed according to the World Health
Organization/International Society of Hypertension guidelines and
were routinely receiving antihypertensive therapy. Patients were
defined as type 2 diabetics if they had known diabetes treated by
diet, oral hypoglycaemic drugs or insulin before stroke.
Previous coronary artery disease was determined on the basis of
a history of physician-diagnosed angina, myocardial infarction, or
any previous revascularization procedure assessed by a question-
naire.
Previous cerebrovascular disease (TIA/ischemic stroke) was
assessed by history, specific neurologic examination performed by
specialists, and hospital or radiological (brain computer tomog-
raphy or brain magnetic resonance) records of definite previous
stroke.
Subjects were classified as having previous peripheral artery
disease (PAD) when they had an history of ABI <0.9 and/or of inter-
mittent claudication or of critical limb ischemia or when they had
undergone a peripheral arterial bypass or amputation.
The study protocol was approved by the local ethics committee,
and all participants gave written informed consent Every subject
with ischemic stroke was matched for age (±3 years), sex, and
cardiovascular risk factor prevalence with one control subject.
The type of acute ischemic stroke was classified according to the
TOAST classification [24]: (1) Large Artery AtheroSclerosis (LAAS);
(2) CardioEmbolic Infarct (CEI); (3) LACunar infarct (LAC); (4) stroke
of Other Determined Etiology (ODE); (5) stroke of UnDetermined
Etiology (UDE).
2.1.1. Large Artery AtheroSclerosis (LAAS)
These patients have clinical and brain imaging findings of either
significant (>50%) stenosis or occlusion of a major brain artery or
branch cortical artery, presumably due to atherosclerosis. Clini-
cal findings include those of cerebral cortical impairment (aphasia,
neglect, restricted motor involvement, etc.) or brain stem or cere-
bellar dysfunction. Cortical or cerebellar lesions and brain stem
or subcortical hemispheric infarcts greater than 1.5 cm in diam-
eter on CT or MRI are considered to be of potential large-artery
atherosclerotic origin. Supportive evidence by duplex imaging or
arteriography of a stenosis of greater than 50% of an appropri-
ate intracranial or extracranial artery is needed. Diagnostic studies
should exclude potential sources of cardiogenic embolism.
2.1.2. CardioEmbolic Infarcts (CEI)
This category includes patients with arterial occlusions pre-
sumably due to an embolus arising in the heart. Cardiac sources
are divided into high-risk and medium-risk groups based on the
evidence of their relative propensities for embolism. At least one
cardiac source for an embolus must be identified for a possible
or probable diagnosis of cardioembolic stroke. Clinical and brain
imaging findings are similar to those described for large-artery
atherosclerosis. Evidence of a previous TIA or stroke in more than
one vascular territory or systemic embolism supports a clinical
diagnosis of cardiogenic stroke. Potential large-artery atheroscle-
rotic sources of thrombosis or embolism should be eliminated.
Stroke in a patient with a medium-risk cardiac source of embolism
and no other cause of stroke is classified as a possible cardioembolic
stroke.
2.1.3. LACunar infarct (LAC)
The patient should have one of the traditional clinical lacunar
syndromes and should not have evidence of cerebral cortical dys-
function. A history of diabetes mellitus or hypertension supports
the clinical diagnosis. The patient should also have a normal CT/MRI
examination or a relevant brain stem or subcortical hemispheric
lesion with a diameter of less than 1.5 cm demonstrated.
2.1.4. Stroke of Other Determined Etiology (ODE)
This category includes patients with rare causes of stroke, such
as non-atherosclerotic vasculopathies, hypercoagulable states, or
hematologic disorders. Patients in this group should have clinical
and CT or MRI findings of an acute ischemic stroke, regardless of the
size or location. Diagnostic studies such as blood tests or arteriog-
raphy should reveal one of these unusual causes of stroke. Cardiac
sources of embolism and large-artery atherosclerosis should be
excluded by other studies.
2.1.5. Stroke of UnDetermined Etiology (UDE)
In some cases, the cause of a stroke cannot be determined with
any degree of confidence. Some patients have no likely etiology
determined despite an extensive evaluation. In others, no cause is
found but the evaluation was cursory.
All the ischemic stroke patients underwent: medical history
with recording of potential stroke risk factors, blood and coag-
ulation tests, 12-lead ECG, 24 h electrocardiography monitoring,
trans-thoracic echocardiography, carotid ultrasound, brain CT or
MRI at admission (repeated between the third and seventh days of
stroke onset).
Neurological deficit score on admission was evaluated by
Scandinavian Stroke Scale (SSS). SSS assesses neurological deficit
through an evaluation of consciousness level, eye movement,
strength in arms, hands, and legs, orientation, language, facial
weakness and gait, giving rise to a score ranging from 58 (absence
of deficit) to 0 (death).
2.2. PWV measurement
Carotid-femoral PWV was measured in the supine position using
the automatic device (SphygmoCor version 7.1) that measured the
time delay between the rapid upstroke of the carotid and femoral
artery pulse waves. The distance between the 2 arterial points was
measured on the surface of the body using a tape measure. PWV
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was calculated as the distance traveled by the arterial pulse wave
(meters) divided by the time delay between the 2 arterial points
(seconds), thus expressed as meters per second.
2.3. Pulse wave analysis
Applanation tonometry was used to record radial artery pres-
sure waveform continuously, and mean values of ≥2 screens of
pulse waves of good quality were used for analysis. On the basis
of the collected data, an averaged radial pressure waveform was
generated and a corresponding aortic pressure waveform and BP
calculated by the validated transfer function (SphygmoCor version
7.1). The aortic pressure waveform was used to calculate the Aix
(difference in height between the first and second systolic peaks
expressed as a percentage of pulse pressure (PP)).
2.4. Laboratory evaluation
Blood samples were obtained in the non-fasting state. After
10 min of rest in the supine position, vital signs were recorded and
blood samples were collected from the antecubital vein.
EDTA-anticoagulated peripheral blood was drawn from each
patient within 12 h from symptom onset. Serum and plasma were
immediately separated by centrifugation and stored in aliquots at
−80 ◦C until analysis.
We evaluated plasma levels of C-reactive protein (CRP),
interleukin-1beta (IL-1), tumor necrosis factor-alpha (TNF-),
interleukin-6 (IL-6) and interleukin-10 (IL-10), E-selectin, P-
selectin, intercellular adhesion molecule-1 (ICAM-1), vascular
cell adhesion molecule-1 (VCAM-1), as markers of immune-
inflammatory activation, von Willebrand Factor (vWF) plasma
levels as a marker of endothelial dysfunction, tissue plasminogen
activator (TPA) and plasminogen activator inhibitor-1 (PAI-1) as
marker of thrombotic/fibrinolytic pathway.
IL-1, TNF-, IL-6 and IL-10 and VWF antigen were mea-
sured using a sandwich ELISA (Human IL-1ˇ, TNF-˛, IL-6 and IL-10
Quantikine, R&D Systems (VWF ELISA kitdurian, Instrumentation
Laboratory, Milano, Italy)); VCAM-1, ICAM-1, E-selectin, P-selectin,
PAI-1 and TPA-antigen were measured by commercial bioim-
munoassay (Human sICAM-1, sVCAM-I, sE-selectin and sP-selectin
Parameter, Quantikine, R&D Systems, Gentaur AssayMax Human
Plasminogen Activator Inhibitor-1 (PAI-1) ELISA Kit, Gentaur Assay-
Max Tissue Plasminogen Activator (TPA) ELISA Kit).
The minimum detectable concentrations for the diagnostic tests
are: TNF alpha: 1.6 pg/ml; IL-1: <1 pg/ml; IL-6: <0.70 pg/ml; IL-10:
>3.9 pg/ml; ICAM-1: <0.35 ng/ml; VCAM-1: 0.6 ng/ml; E-selectin:
<0.1 ng/ml; P-selectin: <0.5 ng/ml; vWF: 1.0%; TPA: 0.3 pg/ml; PAI-
1: <50 pg/ml.
Intraassay and interassay coefficients of variation were: TNF
alpha: 4.2% and 4.6%; IL-1: 3.3% and 4.2%; IL-6: 1.6% and 3.3%;
IL-10: 4.3% and 7.5%; ICAM-1: 4.8% and 6.1%; VCAM-1: 3.5% and
7.7%; E-selectin: 4.8% and 5.7%; P-selectin: 4.9% and 8.8%; vWF: 5%
and 10%; TPA: 4.8% and 5%; PAI-1: 5.7% and 8.3%.
2.5. Statistical analysis
Results are expressed as mean ± SD for continuous variables and
percentages for categorical data, with P ≥ 0.05 considered signifi-
cant. Analysis of normality was performed with the Shapiro–Wilk
W test. Non-normally distributed data were logarithmically
(Log 10) transformed before analysis.
The relationship between immune-inflammatory markers,
PWV, Aix, and other parameters was analyzed using nonparamet-
ric methods (Spearman P correlations) after correction for age and
gender.
According to sample size calculation a sample size of 100
patient-control pairs had 80% power at the 5% significance level
to detect a 10% difference in selected biomarker plasma levels and
arterial stiffness indexes between control subjects and patients and
between each subtype of stroke.
3. Results
We enrolled 107 patients with acute ischemic stroke and 107
control subjects matched for age, sex, cardiovascular risk factors
and previous cardiovascular morbidity.
According to the TOAST criteria, the etiology of stroke was
large-artery atherosclerosis (LAAS) in 41 (38.31%) patients, car-
dioembolism (CEI) in 31 (28.97%) patients, lacunar stroke in 32
(29.92%) patients whereas 3 (2.80%) subjects were classified as ODE.
Baseline patient characteristics are given in Table 1. Subjects with
acute ischemic stroke showed significantly higher plasma levels of
CRP, IL-1 , IL-6 TNF , E-selectin, P-selectin, I-CAM-1, V-CAM-1,
VWF, TPA and PAI-1 (see Table 1). Baseline characteristic of sub-
jects with ischemic stroke with regard of TOAST subtypes are given
in Table 2.
PWV and Aix values in stroke patients and in each TOAST sub-
type are given in Table 1 and in Table 2. Subjects with acute ischemic
stroke showed significantly higher levels of PWV and AIx (see
Table 1) whereas in relation of stroke subtype lacunar subtype
showed the highest value of both arterial stiffness indexes (see
Table 2).
3.1. Relationship between PWV and immune-inflammatory
variables
There was a significant positive relationship, corrected for
age, and gender, between PWV and CRP (r = 0.36; P < 0.001), TNF-
 (r = 0.42; P < 0.001), IL1 (r = 0.35; P < 0.001), VWF (r = 0.46;
P < 0.001), and IL-6 (r = 0.27; P < 0.05) (see Table 3).
3.2. Relationship between Aix and immune-inflammatory
variables
The Aix was significantly related, after correction for age and
gender, to VWF (r = 0.38; P < 0.0001), but not to CRP (r = 0.09;
P = 0.37), IL-6 (r = 0.12; P < 0.08), or TNF- (r = 0.14; P < 0.15) levels
(see Table 3).
3.3. Relationship between PWV and immune-inflammatory
variables in relation to TOAST subtype
Among Lacunar subtype PWV, after correction for age and gen-
der, was significantly and positively related to CRP, IL-1, IL-6,
TNF- and vWF (see Table 4).
In subjects with stroke classified as LAAS, PWV was significantly
and positively related to CRP, IL-1, IL-6, TNF- but not with vWF
(see Table 4).
In CEI subtype, PWV was significantly and positively related to
TNF- and vWF but not with CRP, IL-6, IL-1 (see Table 4).
3.4. Relationship between Aix and immune-inflammatory
variables in relation to TOAST subtype
Among Lacunar and CEI subtype Aix was positively and signifi-
cantly related, after correction for age and gender, only to vWF; in
LAAS subgroup this relationship was significantly weaker and only
close to statistical significance (see Table 4).
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Table 1
General characteristics and immuno-inflammatory variables of stroke patients and controls.
Variable Stroke pts (n: 107) Controls (n: 102) P
Age (years) 71 (63–80.5) 68 (63–80) 0.79
M/F (n) 66/41 57/55 0.022
SBP/DBP (mm/Hg) 151 ± 8.9/96 ± 4.2 141 ± 9.8/91 ± 2.2 <0.001
MAP (mm/Hg) 114.33 ± 9.4 107.6 ± 8.4 <0.005
Diabetes (n/%) 44 (41.12) 41 (40.19%) 0.263
Hypertension (n/%) 50 (45.72%) 46 (45.09%) 0.301
Age (years) 71 (63–80.5) 68 (63–80) 0.79
Glucose blood levels (mg/dl) 148.5 (97–213) 109 (81.5–163.5) <0.001
Cholesterol blood levels (mg/dl) 231 (189–250) 220 (168–215) <0.001
Triglycerids blood levels (mg/dl) 177.5 (130.75–201.75) 141 (96–205) 0.004
White blood cells (per mm3) 9200 (6000–13,000) 7400 (6500–9800) <0.001
Neutrophils (%) 6180 (5071–9000) 4040 (3200–5800) <0.001
Diabetes (n/%) 44 (41.12) 41 (40.19%) 0.263
Hypertension (n/%) 50 (45.72%) 46 (45.09%) 0.301
Aix (%) 103 ± 3.5 89 ± 4.6 <0.001
PWV (m/s) 11.8 ± 3.3 10.02 ± 2.29 <0.001
SSS 30.22 ± 16.21 –
NIHSS 19.41 ± 10.06 –






Death (n/%) 7 (6.5) – <0.001
CAD (n/%) 38 (35.51) 37 (36.27) 0.44
CHF (n/%) 21 (19.62) 15 (14.70) 0.065
Previous TIA (n/%) 40 (37.38) 11 (10.87) <0.001
Previous stroke (n/%) 33 (30.84) 7 (6.82) <0.001
Microalbuminuria (n/%) 41 (38.31) 18 (17.64) <0.001
Carotid plaque (n/%) 61 (57) 33 (32.35)I <0.001
LVH (n/%) 45 (42.05) 21 (20.58) <0.001
Previous brain infarct at
neuroimage (n/%)
40 (37.38) 19 (18.62) <0.001
WMHLS (n/%) 27 (25.23) 18 (17.64) 0.024
CRP (mg/dl) 3.8 ± 2.2 1.9 ± 0.9 <0.05
IL-1- (pg/ml) 8 (5–10) 4 (2–5) <0.001
IL-6 (pg/ml) 10 (6–28) 8 (3.1–12) <0.001
TNF- (pg/ml) 30.5 (10.25–46) 5.1 (1.1–4.3) <0.001
E-selectin (ng/ml) 2.05 (1.0–3.8) 2 (1–2) <0.001
P-selectin (ng/ml) 4.5 (2–6.8) 3.1 (2.1–4) 0.004
VICAM (ng/ml) 16 (10.1–20) 10 (7–15) <0.001
ICAM (ng/ml) 18.8 (12.2–20) 10.9 (12–16.1) <0.001
IL-10 (pg/ml) 3.95 (2–7) 4 (2–10) 0.233
vWF (ng/ml) 11 (6–15) 4 (3–9) 0.0001
PAI-1 (pg/ml) 137 (99.5–155) 23 (11–24) <0.001
TPA (pg/ml) 21 (10.55–39) 55 (29–88) <0.001
Premorbid antithrombotics
Antiplatelets (n/%) 41 (38.31) 34 (33.33) 0.74
Anticoagulants (n/%) 33 (30.84) 27 (26.47) 0.54
Premorbid cardiovascular drugs
Ace-inhibitors (n/%) 39 (36.44) 30 (29.41) 0.041
ARBs (n/%) 28 (26.18) 21 (20.58) 0.40
Statins (n/%) 42 (39.25) 32 (31.37) 0.35
Antidiabetic drugs (n/%) 21 (19.62) 22 (21.50) 0.21
Biguanids (n/%) 12 (11.21) 14 (13.72) 0.35
Sulphonilureas (n/%) 9 (8.41) 8 (7.8) 0.67
Thiazolidinediones (n/%) – –
Insulin (n/%) 23 (21.49) 19 0.28
SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure; Aix: augmentation index; PWV: pulse wave
velocity; SSS: Scandinavian Stroke Scale score; NIHSS: National Institutes of Health Stroke Scale; Angiotensin II receptor blockers
(ARBs); CAD: coronary artery disease; CHF: congestive heart failure; LVH: left ventricular hypertrophy; WMHLS: white matter hyper-
intensity lesions; TIA: transitory ischemic attack; CRP: C-reactive protein; TNF-: tumor necrosis factor ; IL-1: interleukin-1-; IL-6:
interleukin-6; IL-10: interleukin 10; ICAM-1: intercellular adhesion molecule-1; VCAM-1: vascular cell adhesion molecule-1; vWF: von
Willebrand Factor; TPA: tissue plasminogen activator; PAI-1: plasminogen activator inhibitor-1.
Immuno-inflammatory and thrombotic-fibrinolytic variables are expressed as median and interquartile (lower and upper quartile).
Demographic and anamnestic data are expressed as no. (percentage).
4. Discussion
The main our findings were that patients with acute ischemic
stroke had both increased inflammatory markers and arterial stiff-
ness markers compared to control subjects without acute ischemic
stroke.
This is the first study to show in patients with acute ischemic
stroke that circulating levels of some immune-inflammatory mark-
ers such as CRP, IL-6, IL-1, TNF- and VWF are related to PWV and
wave reflection.
Large artery stiffness is now recognized as a modifiable,
independent predictor of cardiovascular risk [26,27]. Structural
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Table 2
Premorbid cardiovascular risk factors, clinical characteristics and antithrombotic medication by ischemic stroke subtype.
Variable Lacunar LAAS CEI ODE P
Number 32 41 31 3
Age (years) 76.31 ± 7.37 72.17 ± 6.83 76.00 ± 8.79 49.00 ± 45.50 <0.001
Sex (M/F) 19/12 29/12 23/8 4/0 <0.001
Diabetes (n/%) 17 (56.25) 18 (43.90) 9 (29.03) 0 <0.001
Hypertension (n/%) 18 (56.2) 17 (41.46) 14 (45.16) 1 (33.33) 0.25
Hypercholesterolaemia (n/%) 7 (21.87) 16 (39.02) 9 (29.03) 0 <0.05
Atrial fibrillation (n/%) 3 (9.3) 5 (12.19) 24 (77.41) 0 <0.001
Previous TIA (n/%) 5 (15.6) 13 (31.07) 10 (32.2) 1 (33.3%) <0.001
Previous stroke (n/%) 7 (21.8) 8 (19.5) 7 (22.05) 2 (66.66) 0.038
Glucose blood levels (mg/dl) 169.12 ± 74.06 117.00 ± 53.44 102.29 ± 7.68 92.29 ± 17.68 <0.001
Total cholesterol blood levels (mg/dl) 179.56 ± 40.07 175.02 ± 46.42 165.71 ± 30.64 169.00 ± 49.46 <0.05
LDL cholesterol (mg/dl) 95.62 ± 38.65 103.247 ± 28.9 84.67 ± 33.99 99.20 ± 32.81 <0.05
Trygliceride blood levels (mg/dl) 170.16 ± 82.40 190.82 ± 162.12 112.35 ± 32.36 148.00 ± 83.439 <0.05
WBC (per mm3) 10041.37 ± 4167.31 11742.82 ± 9267.20 16282.41 ± 2556.64 10785.00 ± 5437.65 <0.05
Neutrophile (%) 7384.51 ± 3769.68 7803.87 ± 4303.00 6996.13 ± 3107.86 8418.00 ± 7481.19 <0.05
HCT (%) 39.20 ± 3.9 40.70 ± 4.24 41.386 ± 3.196 38.25 ± 9.54 0.041
SB P/DBP (mm/Hg) 153 ± 9.5/96 ± 4.2 151 ± 6.5/95 ± 4.2 149 ± 9.8/93 ± 2.2 145 ± 5.8/91 ± 2.5 <0.05
MAP (mm/Hg) 115 ± 9.7 113.6 ± 10.1 111.6 ± 8.2 109 ± 6.7 <0.05
Aix (%) 112 ± 5.5 108 ± 3.5 99 ± 3.5 101 ± 3.5 <0.05
PWV (m/s) 12.04 ± 1.54 11.98 ± 2.445 10.40 ± 2.445 11.48 ± 1.345 <0.05
NIHSS 14.65 ± 14.59 20.51 ± 16.06 15.64 ± 8.73 19.00 ± 12.72 <0.05
msRankin score at discharge (n/%)
I 8 (25) 7 (17.07) 4 (12.90) 1 (25)
II 13 (18.75) 6 (14.63) 3 (9.6) –
III 6 (40.62) 9 (21.95) 5 (16.19) 2 (50)
IV 3 (9.37) 10 (24.39) 10 (32.22) 1 (25)
V 2 (6.25) 9 (21.95) 9 (29.03) –
Death (n/%) – 2 (4.8) 5 (16.12) –
CAD (n/%) 13 (40.6) 18 (43.91) 7 (22.58) 0
CHF (n/%) 4 (12.5) 5 (12.19) 11 (35.48) 1 (33.33)
Microalbuminuria (n/%) 24 (75%) 11 (26.82) 6 (19.35) 0 <0.001
Carotid plaque (n/%) 22 (68.7) 27 (65.85) 14 (45.16) 0 <0.05
LVH (n/%) 18 (56.25) 17 (41.46) 10 (32.25) 0 <0.05
Previous brain infarct at
neuroimaging (n/%)
13 (40.62) 15 (36.58) 10 (32.2) 2 (66.66) 0.65
WMHLS (n/%) 13 (40.6) 8 (25.80) 5 (16.1) 1 (66.66) <0.05
CRP (mg/dl) 2.8 ± 2.1 3.9± 3.1 ± 1.7 1.8 ± 0.9 0.041
IL-1- (pg/ml) 5 (4–9) 8 (6–11) 11 (6–12) 7 (5–11) <0.05
IL-6 (pg/ml) 8 (6–21) 10 (5–25) 12 (6–29) 10 (6–28) <0.05
TNF- (pg/ml) 22.5 (8.5–26) 30.5 (11.25–40) 39.5 (24–55) 32.5 (10.25–46) <0.05
E-selectin (ng/ml) 3.05 (1.5–3.7) 2.45 (1.6–3.9) 3.05 (2.0–4.0) 2.05 (1.0–3.8) 0.035
P-selectin (ng/ml) 3.5 (2–4.8) 4.4 (2–6.0) 4.6 (2–6.9) 4.5 (2–6.8) 0.71
VICAM (ng/ml) 16 (9.1–18) 14 (10.2–21) 17 (10.1–22) 16 (10.51–20) 0.67
ICAM (ng/ml) 16.8 (11.2–18) 17.9 (10.2–210) 20.6 (11.2–24) 17.8 (13.2–21) 0.041
IL-10 (pg/ml) 3.55 (2–6) 3.96 (2–8) 3.2 (2–9) 3.95 (2–7) 0.65
vWF (ng/ml) 10 (4–17) 12 (5–13) 14 (6–18) 11 (7–116) 0.021
PAI-1 (pg/ml) 139 (90.5–143) 138 (91.5–135) 139 (99.0–145) 137 (99.5–155) 0.34
TPA (pg/ml) 23 (10.15–37) 23 (10.45–41) 24 (12.1–47) 22 (10.55–39) 0.81
Premorbid antithrombotics
Antiplatelets (n/%) 11 (38.31) 20 (48.78) 10 (32.22) – <0.05
Anticoagulants (n/%) 4 (12.5) 7 (17.07) 21 (67.74) 1 <0.001
Premorbid cardiovascular drugs
Ace-inhibitors (n/%) 18 (56.25) 11 (26.82) 10 (32.25) – <0.05
ARBs (n/%) 10 (31.25) 11 (26.82) 7 (22.58) – 0.041
Statins (n/%) 15 (46.87) 20 (48.78) 7 (22.58) 0.031
Antidiabetic drugs (n/%)
Biguanids (n/%) 10 (31.25) 7 (17.07) 4 (12.9) – <0.05
Sulphonilureas (n/%) 6 (18.75) 3 (7.31) 2 (6.45) <0.05
Thiazolidinediones (n/%) 4 (12.5) 4 (9.7) 2 (6.45) <0.025
Insulin (n/%) 11 (34.37) 6 (14.63) 6 (19.35) – <0.05
SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure; Aix: augmentation index; PWV: pulse wave velocity; SSS: Scandinavian Stroke
Scale score; NIHSS: National Institutes of Health Stroke Scale; Angiotensin II receptor blockers (ARBs); CAD: coronary artery disease; CHF: congestive heart failure; LVH: left
ventricular hypertrophy; WMHLS: white matter hyperintensity lesions; CRP: C-reactive protein; TNF-: tumor necrosis factor ; IL-1: interleukin-1-; IL-6: interleukin-
6; IL-10: interleukin 10; ICAM-1: intercellular adhesion molecule-1; VCAM-1: vascular cell adhesion molecule-1; vWF: von Willebrand Factor; TPA: tissue plasminogen
activator; PAI-1: PAI-1: plasminogen activator inhibitor-1.
Immuno-inflammatory and thrombotic-fibrinolytic variables are expressed as median and interquartile (lower and upper quartile).
Demographic and anamnestic data are expressed as no. (percentage).
Significative R and P are in bold.
components within the arterial wall, mainly collagen and elastin,
together with transmural pressure, are key determinants of large
vessel stiffness. However, smooth muscle tone also influences the
stiffness of elastic and muscular arteries, suggesting functional reg-
ulation of stiffness by local and/or circulating vasoactive substances
[28–30]. Interestingly, acute systemic inflammation has recently
been associated with endothelial dysfunction in vivo [31–33].
Our findings show that both aortic stiffness and wave reflec-
tion are related to the degree of systemic inflammation in stroke
subjects, suggesting that circulating inflammation mediators such
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Table 3
Correlations of pulse wave velocity (PWV) and augmentation index (Aix) with
immuno-inflammatory variables in stroke patients.
Variable Pulse wave velocity Augmentation index (Aix)
R P-values R P-values
CRP 0.36 <0.001 0.09 0.37
IL-1- 0.35 <0.001 0.10 0.22
IL-6 0.27 <0.05 0.12 0.35
TNF- 0.42 <0.001 0.14 0.15
E-selectin 0.13 0.42 0.12 0.22
P-selectin 0.11 0.56 0.12 0.35
VICAM-1 0.08 0.37 0.08 0.37
ICAM-1 0.10 0.7 0.10 0.7
IL-10 0.11 0.81 0.10 0.77
vWF 0.46 <0.001 0.38 <0.0001
PAI-1 0.12 0.42 0.13 0.32
TPA 0.15 0.42 0.14 0.36
Coefficients (R) and P-values are calculated by the Pearson correlation mode.
CRP: C-reactive protein; TNF-: tumor necrosis factor ; IL-1: interleukin-1-;
IL-6: interleukin-6; IL-10: interleukin 10; ICAM-1: intercellular adhesion molecule-
1; VCAM-1: vascular cell adhesion molecule-1; vWF: von Willebrand Factor; TPA:
tissue plasminogen activator; PAI-1: PAI-1: plasminogen activator inhibitor-1.
Significative R and P are in bold.
as CRP and some pro-inflammatory cytokines can influence the
stiffness of vessels distant to those involved in the disease process
itself.
Previous studies in healthy subjects have shown a positive rela-
tionship between either PWV or Aix with CRP but not with both
[9,10], whereas Mahmud and Feely [22] showed in hypertensive
patients a relationship between augmentation index to IL-6 and
TNF-.
PWV is a classic marker of aortic stiffness, whereas Aix is far
more complex and is composed of the magnitude of arterial wave
reflection, PWV, and pattern of left ventricular ejection. Also, the
determinants of these indices differ. Aix is influenced to a greater
extent by the level of heart rate, BP, gender, age, and height,
whereas PWV is predominantly determined by age and BP [25].
Aix and PWV represent not only large artery stiffness but,
very importantly, the vascular smooth muscle tone in the periph-
eral medium-sized muscular arteries, emphasizing the systemic
nature of the inflammatory response encompassing biochemical
and hemodynamic parameters. Cytokine plasma levels in its turn
also influences vascular vulnerability to the inflammatory response
and decreased production of the endogenous vasodilator nitric
oxide (NO) [34]. Inhibition of basal NO synthesis increases aortic
Aix and velocity in vivo [35].
An immune-inflammatory cascade occurs after an acute
ischemic stroke [5,6] so on this basis cytokine levels that we
reported and measured 72 h from symptom onset express an acute
rise of these inflammatory markers.
Our group [3,4] recently showed some differences in acute
immune-inflammatory activation with regard of plasma levels of
inflammatory markers between each diagnostic subtype of stroke.
We also evaluated the predictive value of a series of can-
didate serum immuno-inflammatory and thrombotic/fibrinolitic
molecules towards diagnosis of acute ischemic stroke showing that
TNF-, PAI-1 and TPA on bivariate logistic regression were highly
correlated to stroke diagnosis [7].
Furthermore [8] we recently reported that patients with acute
ischemic stroke in comparison with patients without stroke show
higher arterial stiffness index values and that among stroke
patients, lacunar subtype has the highest arterial stiffness indexes.
On this basis it’s possible to hypothesize a possible relationship
between acute immuno-inflammatory cascade and acute arterial
stiffness increase in patients with acute ischemic stroke and our
findings concerning a relationship between some cytokines plasma
levels and PWV and Aix may represent a possible confirmation of
this association.
What is the relationship between acute high levels of cytokines
and arterial stiffness indexes in stroke patients? Does a hyper-acute
inflammatory state after ischemic stroke directly cause increase
of arterial stiffness? Or in stroke-prone patients with a chronic
inflammatory activation exacerbated by acute stressor events such
an acute cerebrovascular event, does it represent the pathogenetic
basis of high arterial stiffness?
It’s difficult to answer; nevertheless, it’s possible to obtain an
answer to the question about the relationship between inflamma-
tion markers and arterial stiffness indexes in acute ischemic stroke
by evaluating our findings of some significant correlations at intra-
group analysis in each TOAST subtype between arterial stiffness
indexes and immune-inflammatory markers.
For instance, only in lacunar subtype we observed a strong cor-
relation between PWV and IL6, IL-1, TNF- and vWF, whereas in
LAAS we did not report any correlation with vWF and in the CEI
group we reported only a positive relation with TNF- and vWF.
Moreover evidence has shown that platelet reactivity is higher
in patients following ischemic stroke [34,36]. The correlation
between vWF and arterial stiffness markers does not indicate a
direct biological background although the possible inflammatory
role recently demonstrated for vWF [35,37], could explain the rela-
tionship with arterial stiffness indexes.
Table 4
Correlations of pulse wave velocity (PWv) and augmentation index (Aix) with immuno-inflammatory variables in stroke patients in relation of TOAST stroke subtype.
Variables Lacunar LAAS CEI
PWV Aix PWV Aix PWV Aix
R P R P R P R P R P R P
CRP 0.37 <0.001 0.022 0.19 0.35 <0.001 0.33 0.022 0.22 0.06 0.12 0.78
IL-1- 0.272 <0.05 0.25 0.121 0.32 <0.05 0.11 0.27 0.20 0.07 0.18 0.980
IL-6 0.27 <0.05 0.12 0.10 0.29 <0.05 0.12 0.022 0.19 0.567 0.12 0.78
TNF- 0.36 <0.001 0.11 0.121 0.35 <0.001 0.10 0.27 0.34 <0.001 0.18 0.980
E-selectin 0.022 0.19 0.08 0.11 0.15 0.27 0.13 0.10 0.16 0.267 0.12 0.78
P-selectin 0.25 0.121 0.09 0.12 0.12 0.022 0.12 0.11 0.18 0.98 0.18 0.980
VICAM 0.10 0.19 0.70 0.07 0.15 0.27 0.12 011 0.18 0.98 0.14 0.68
ICAM 0.09 0.10 0.014 0.19 0.14 0.48 0.33 0.022 0.0367 0.12 0.10 0.788
IL-10 0.11 0.121 0.12 0.121 0.25 <0.05 0.19 0.27 0.19 0.32 0.12 0.78
vWF 0.39 <0.001 0.38 <0.001 0.21 0.065 0.20 0.06 0.39 <0.001 0.37 <0.001
PAI-1 0.11 0.19 0.12 0.20 0.13 0.21 0.08 0.78 0.022 0.19 0.12 0.78
TPA 0.12 0.20 0.13 0.21 0.14 0.22 0.12 0.20 0.11 0.19 0.132 0.980
Coefficients (R) and P-values are calculated by the Pearson correlation mode.
CRP: C-reactive protein; TNF-: tumor necrosis factor ; IL-1: interleukin-1-; IL-6: interleukin-6; IL-10: interleukin 10; ICAM-1: intercellular adhesion molecule-1; VCAM-
1: vascular cell adhesion molecule-1; vWF: von Willebrand Factor; TPA: tissue plasminogen activator; PAI-1: PAI-1: plasminogen activator inhibitor-1.
Significative R and P are in bold.
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On this basis it is possible that observed differences with
regard to the relationship between arterial stiffness indexes and
inflammatory markers could be related to differences in immune-
inflammatory activation of the acute phase of each TOAST diagnos-
tic subtype.
Cardioembolic stroke could appear as the “less atherosclerotic”
among each diagnostic subtype of stroke and this finding could
explain the correlation only with CRP and vWF, although our group
recently demonstrated that this subtype of acute ischemic stroke
is characterized by the highest degree of immune-inflammatory
activation of the acute phase [38].
Our finding concerning some differences in the observed cor-
relation between immune-inflammatory markers and arterial
stiffness indexes in relation to each TOAST subtype of stroke might
also indicate a different degree of vascular anatomy impairment
or a different distribution of certain risk factors already reported
as related to the inflammation markers, such as hypertension and
diabetes. In fact our patients with lacunar stroke, in which both
CRP, IL-6, IL-1, TNF- and vWF are related to PWV, have an
higher frequency of both hypertension and diabetes and this find-
ing allow it to represent, in some ways the prototype of the acute
cerebrovascular event in diabetic or hypertensive subjects. Fur-
thermore the molecular events associated with remodelling of the
large and medium to small arteries also have been well char-
acterized and involve the combinatorial influences of adhesion
molecules, integrins, metallo-proteinases, the renin-angiotensin
axis, and inflammation on the cellular constituents (endothelial
cells, vascular smooth cells, fibroblasts, and matrix components)
of the vasculature [39,40,42].
Biomarkers of inflammation like CRP, interleukin-6, and tumor
necrosis factor- have been associated positively with both indi-
rect (e.g. brachial artery pulse pressure) [41] and direct measures of
arterial stiffness in previous studies in apparently healthy individ-
uals, [9] in specific patient groups (e.g. patients with hypertension)
[22], and in community-based samples [43–45]. Most of these
studies had modest sample sizes, but no study evaluated the
relationship between stiffness indexes and immune-inflammatory
markers in patients with acute ischemic stroke or other acute car-
diovascular event, so our findings appear novel.
A number of possible confounding factors (including additional
cardiovascular risk factors, smoking, and other clinical variables
as well as pharmacological and non pharmacological treatments)
might negatively confound our observed findings. Nevertheless,
we compared our patients with acute ischemic stroke patients
with matched controls for cardiovascular risk factor. Moreover, we
observed no significant difference between case and controls with
regard of treatment with ace-inhibitors, ARBs, statins and antidia-
betic drugs, potentially able to interfere with vascular inflammation
and arterial stiffness markers.
Only one study examined the relationship between arterial stiff-
ness markers and an inflammation marker in subjects with acute
ischemic stroke [23].
These authors studied the relationship of arterial stiffness,
measured by carotid-femoral pulse wave velocity and inflamma-
tion, measured by serum erythrocyte sedimentation rate among
334 ischemic stroke patients. There was a significant correla-
tion between carotid-femoral pulse wave velocity and erythrocyte
sedimentation rate (P = 0.001), a relationship independent of age,
hypertension, diabetes and smoking.
The same authors examined the relationship also investigated
the role of inflammation measured by serum erythrocyte sedi-
mentation rate (ESR) in the metabolic syndrome-arterial stiffness
relationship amongst 229 prospectively recruited acute ischemic
stroke patients, we measured carotid-femoral PWV using appla-
nation tonometry and the inflammatory marker serum ESR.
They showed that Carotid-femoral PWV was significantly higher
amongst patients with MetS (P, increased waist circumference,
raised blood pressure and abnormal glycemia and increased with
the number of MetS components).
Our study is the first study that analyzed in patients with
acute cerebrovascular events, the relationship between markers
of immuno-inflammatory activation such as plasma levels of pro-
inflammatory cytokines and both markers of arterial stiffness such
as pulse wave velocity (PWV) and augmentation index (Aix) and
thus providing a possible explanation for increased arterial stiffness
in patients with acute ischemic stroke [46].
Possible limitations of our study are that our findings corrobo-
rate previous observational data showing an association between
arterial stiffness and inflammatory markers but it does not pro-
vide an explanatory causative link for these associations. Previous
studies have shown that exogenously administered cytokines
(specifically IL-1) cause a NO-mediated basal vasodilation in
human veins by inducing the constitutively expressed endothe-
lial nitric oxide (NO)-synthase [45]. Nevertheless in acute ischemic
stroke excitotoxic or ischemic conditions excessively activate
nNOS, resulting in concentrations of NO that are toxic to surround-
ing neurons [47]. But what are extra-cerebral large artery levels
of NO in ischemic stroke subjects? No study to our knowledge
analyzed this issue.
Another possible limitation because of technical limitations
with regard of Aix evaluation is that we recruited in patients with
cardioembolic subtype of stroke patients subjects with atrial fib-
rillation. However, other studies that have assessed the markers of
arterial stiffness in patients with atrial fibrillation, have evaluated
both PWV and Aix [48,49].
Maybe an acute NO depletion role is not directly presumable to
explain an acute rise in arterial stiffness in acute stroke patients.
For this series of limitations whether our findings can be extended
to a chronic situation is a matter of discussion that future stud-
ies should be clarify evaluating arterial stiffness indexes change in
subjects at cerebrovascular risk before and after an acute ischemic
cerebrovascular event.
The arterial changes have a multitude of potential intercon-
nected causes including endothelial dysfunction, oxidative stress,
inflammation, atherosclerosis and vascular calcification. The role
and contribution of the biochemical changes to arterial stiffness in
the acute phase ischemic stroke is not known, but it’s likely that
immune-inflammatory activation, acute hyperglycemia, endothe-
lial dysfunction and other toxic effects could be responsible of a
acute increase of arterial stiffness after ischemic stroke.
This finding may have potential therapeutic applications aimed
to reducing arterial stiffness by interfering with these biochemical
changes of acute phase after ischemic stroke by means neuro-
protective agents like anti-inflammatory or anti-oxidizing agents
or cardiovascular drug with potential pleiotropic actions such as
statins.
In conclusion we reported that both aortic stiffness and wave
reflection are related to the degree of systemic inflammation
in stroke subjects, showing a significant relationship between
immuno-inflammatory marker and PWV in LAAS and lacunar
subtype of stroke and suggesting that circulating inflammation
mediators after acute ischemic stroke can influence the stiffness
of vessels distant to those involved in the disease process itself.
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